Ligand Pharmaceuticals Inc (LGND) Stock Analysis
Verdict: BUY
Ligand's 98.6% gross margin royalty model generates high-margin cash flow, but milestone lumpiness and partner risks require entry discipline.
Investment score: 68/100
Analysis as of
Is Ligand Pharmaceuticals Inc stock worth reviewing? AI model thesis
The AI model evaluates Ligand Pharmaceuticals as a BUY, supported by 98.6% gross margins, robust forward EPS consensus ($12.11 in 2027), and valuation metrics that trade at a discount to direct profitable sector peers.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 62/100 (weight 15%)
- Earnings Quality: 72/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Ligand Pharmaceuticals Inc opportunities and risks
What speaks for LGND
- Ultra-High-Margin Royalty Aggregation Model
What speaks against LGND
- Concentration and Partner Dependence Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LGND | 28.1x | 19.4x | 21.0x | 98.6% | 67.9% | 2.3% |
| BLTE | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| LQDA | 44.8x | 13.9x | 34.3x | 92.5% | 30.7% | 1.0% |
| AMRX | 37.5x | 1.9x | 13.2x | 39.3% | 5.0% | 1.4% |
| DFTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.2% |
| EWTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.1% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
Frequently asked questions about Ligand Pharmaceuticals Inc (LGND)
Is LGND stock a good investment?
The cached TradeMates AI model rates Ligand Pharmaceuticals Inc as BUY with an investment score of 68/100. The AI model evaluates Ligand Pharmaceuticals as a BUY, supported by 98.6% gross margins, robust forward EPS consensus ($12.11 in 2027), and valuation metrics that trade at a discount to direct profitable sector peers. This is algorithmic model output, not personal investment advice.
Is LGND stock a buy?
The TradeMates model verdict for LGND is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.